nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—MPO—Carboplatin—bone cancer	0.385	0.539	CbGbCtD
Octreotide—MPO—Cisplatin—bone cancer	0.329	0.461	CbGbCtD
Octreotide—SSTR1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00635	0.0656	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—FOLR1—bone cancer	0.00589	0.0609	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—FEV—bone cancer	0.0052	0.0537	CbGpPWpGaD
Octreotide—SSTR2—GPCRs, Other—GRM1—bone cancer	0.00271	0.028	CbGpPWpGaD
Octreotide—SSTR4—G alpha (i) signalling events—RGS1—bone cancer	0.00246	0.0254	CbGpPWpGaD
Octreotide—SSTR4—G alpha (i) signalling events—GRM4—bone cancer	0.00246	0.0254	CbGpPWpGaD
Octreotide—SSTR2—GPCRs, Other—SMO—bone cancer	0.00191	0.0197	CbGpPWpGaD
Octreotide—SSTR3—G alpha (i) signalling events—RGS1—bone cancer	0.00186	0.0193	CbGpPWpGaD
Octreotide—SSTR3—G alpha (i) signalling events—GRM4—bone cancer	0.00186	0.0193	CbGpPWpGaD
Octreotide—SSTR1—G alpha (i) signalling events—GRM4—bone cancer	0.00179	0.0185	CbGpPWpGaD
Octreotide—SSTR1—G alpha (i) signalling events—RGS1—bone cancer	0.00179	0.0185	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—DHFR—bone cancer	0.00162	0.0167	CbGpPWpGaD
Octreotide—SSTR5—G alpha (i) signalling events—RGS1—bone cancer	0.00158	0.0164	CbGpPWpGaD
Octreotide—SSTR5—G alpha (i) signalling events—GRM4—bone cancer	0.00158	0.0164	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—GRM4—bone cancer	0.00149	0.0154	CbGpPWpGaD
Octreotide—SSTR2—G alpha (i) signalling events—GRM4—bone cancer	0.00146	0.0151	CbGpPWpGaD
Octreotide—SSTR2—G alpha (i) signalling events—RGS1—bone cancer	0.00146	0.0151	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—GRM1—bone cancer	0.00129	0.0133	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—GRM4—bone cancer	0.00113	0.0117	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—GRM4—bone cancer	0.00108	0.0112	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—GRM1—bone cancer	0.000979	0.0101	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—GRM4—bone cancer	0.00096	0.00991	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—GRM1—bone cancer	0.000938	0.00969	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—SMO—bone cancer	0.00091	0.0094	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—GRM4—bone cancer	0.000886	0.00915	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—RGS1—bone cancer	0.000842	0.00869	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—GRM4—bone cancer	0.000842	0.00869	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—GRM1—bone cancer	0.000832	0.0086	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—GRM1—bone cancer	0.000768	0.00793	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—GRM4—bone cancer	0.000764	0.0079	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—RGS1—bone cancer	0.000764	0.0079	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—GRM1—bone cancer	0.00073	0.00754	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—SMO—bone cancer	0.000689	0.00712	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—GRM1—bone cancer	0.000663	0.00685	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—SMO—bone cancer	0.000661	0.00683	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—KIT—bone cancer	0.000659	0.00681	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—GRM4—bone cancer	0.000638	0.00659	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—RGS1—bone cancer	0.000638	0.00659	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—GRM4—bone cancer	0.000611	0.00632	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—RGS1—bone cancer	0.000611	0.00632	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—SMO—bone cancer	0.000586	0.00606	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—GRM4—bone cancer	0.000579	0.00598	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—RGS1—bone cancer	0.000579	0.00598	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—GRM4—bone cancer	0.000555	0.00574	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—RGS1—bone cancer	0.000555	0.00574	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—GRM1—bone cancer	0.000553	0.00571	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—GRM4—bone cancer	0.000542	0.0056	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—RGS1—bone cancer	0.000542	0.0056	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—SMO—bone cancer	0.000541	0.00559	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—GRM1—bone cancer	0.00053	0.00548	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—GRM1—bone cancer	0.000502	0.00519	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000502	0.00519	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—PTGS2—bone cancer	0.0005	0.00517	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—RGS1—bone cancer	0.0005	0.00517	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—GRM4—bone cancer	0.0005	0.00517	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—GRM4—bone cancer	0.000492	0.00509	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—RGS1—bone cancer	0.000492	0.00509	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—PTGS2—bone cancer	0.000482	0.00498	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—GRM1—bone cancer	0.000481	0.00497	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—GNA11—bone cancer	0.00047	0.00486	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—GRM1—bone cancer	0.00047	0.00486	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—SMO—bone cancer	0.000467	0.00482	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—GRM4—bone cancer	0.000454	0.0047	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—RGS1—bone cancer	0.000454	0.0047	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—RGS1—bone cancer	0.000451	0.00466	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—GRM4—bone cancer	0.000451	0.00466	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—GRM1—bone cancer	0.000434	0.00448	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—GNA11—bone cancer	0.000427	0.00441	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—GRM1—bone cancer	0.000427	0.00441	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—IL3—bone cancer	0.000426	0.0044	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—JUN—bone cancer	0.000411	0.00424	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—GRM1—bone cancer	0.000394	0.00407	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—GRM1—bone cancer	0.000391	0.00404	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—IL3—bone cancer	0.000387	0.004	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—TP53—bone cancer	0.000361	0.00373	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—GNA11—bone cancer	0.000356	0.00368	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—SMO—bone cancer	0.000354	0.00366	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—GRM4—bone cancer	0.000342	0.00353	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—RGS1—bone cancer	0.000342	0.00353	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—GNA11—bone cancer	0.000342	0.00353	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—SMO—bone cancer	0.000339	0.0035	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—GRM4—bone cancer	0.000328	0.00339	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—RGS1—bone cancer	0.000328	0.00339	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—GNA11—bone cancer	0.000324	0.00334	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—IL3—bone cancer	0.000323	0.00334	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—GNA11—bone cancer	0.00031	0.00321	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—IL3—bone cancer	0.00031	0.0032	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—GNA11—bone cancer	0.000303	0.00313	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—SMO—bone cancer	0.000301	0.00311	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—GRM1—bone cancer	0.000297	0.00306	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—IL3—bone cancer	0.000293	0.00303	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—GRM4—bone cancer	0.000291	0.00301	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—RGS1—bone cancer	0.000291	0.00301	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—GRM1—bone cancer	0.000284	0.00294	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—IL3—bone cancer	0.000281	0.00291	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—GNA11—bone cancer	0.00028	0.00289	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—SMO—bone cancer	0.000278	0.00287	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—SMO—bone cancer	0.000276	0.00285	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—GNA11—bone cancer	0.000275	0.00284	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—IL3—bone cancer	0.000275	0.00284	CbGpPWpGaD
Octreotide—Feeling abnormal—Cisplatin—bone cancer	0.000273	0.00144	CcSEcCtD
Octreotide—Weight increased—Epirubicin—bone cancer	0.000272	0.00143	CcSEcCtD
Octreotide—Haematuria—Methotrexate—bone cancer	0.000271	0.00143	CcSEcCtD
Octreotide—Pancreatitis—Doxorubicin—bone cancer	0.000271	0.00143	CcSEcCtD
Octreotide—Weight decreased—Epirubicin—bone cancer	0.00027	0.00142	CcSEcCtD
Octreotide—Hyperglycaemia—Epirubicin—bone cancer	0.00027	0.00142	CcSEcCtD
Octreotide—Hepatobiliary disease—Methotrexate—bone cancer	0.000269	0.00142	CcSEcCtD
Octreotide—Epistaxis—Methotrexate—bone cancer	0.000269	0.00141	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—RGS1—bone cancer	0.000268	0.00277	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—GRM4—bone cancer	0.000268	0.00277	CbGpPWpGaD
Octreotide—Pneumonia—Epirubicin—bone cancer	0.000268	0.00141	CcSEcCtD
Octreotide—Drowsiness—Epirubicin—bone cancer	0.000266	0.0014	CcSEcCtD
Octreotide—Bronchitis—Doxorubicin—bone cancer	0.000266	0.0014	CcSEcCtD
Octreotide—Body temperature increased—Cisplatin—bone cancer	0.000262	0.00138	CcSEcCtD
Octreotide—Neuropathy peripheral—Epirubicin—bone cancer	0.000261	0.00138	CcSEcCtD
Octreotide—Jaundice—Epirubicin—bone cancer	0.00026	0.00137	CcSEcCtD
Octreotide—Conjunctivitis—Epirubicin—bone cancer	0.000259	0.00136	CcSEcCtD
Octreotide—Urinary tract infection—Epirubicin—bone cancer	0.000259	0.00136	CcSEcCtD
Octreotide—Dysuria—Doxorubicin—bone cancer	0.000259	0.00136	CcSEcCtD
Octreotide—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000257	0.00135	CcSEcCtD
Octreotide—Hepatitis—Methotrexate—bone cancer	0.000256	0.00135	CcSEcCtD
Octreotide—Pollakiuria—Doxorubicin—bone cancer	0.000255	0.00135	CcSEcCtD
Octreotide—Haematuria—Epirubicin—bone cancer	0.000254	0.00134	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—GNA11—bone cancer	0.000254	0.00262	CbGpPWpGaD
Octreotide—Pharyngitis—Methotrexate—bone cancer	0.000254	0.00134	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—IL3—bone cancer	0.000254	0.00262	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—GRM1—bone cancer	0.000252	0.00261	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—GNA11—bone cancer	0.000252	0.00261	CbGpPWpGaD
Octreotide—Hepatobiliary disease—Epirubicin—bone cancer	0.000252	0.00133	CcSEcCtD
Octreotide—Weight increased—Doxorubicin—bone cancer	0.000252	0.00133	CcSEcCtD
Octreotide—Epistaxis—Epirubicin—bone cancer	0.000251	0.00132	CcSEcCtD
Octreotide—Weight decreased—Doxorubicin—bone cancer	0.00025	0.00132	CcSEcCtD
Octreotide—Sinusitis—Epirubicin—bone cancer	0.00025	0.00132	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—IL3—bone cancer	0.000249	0.00258	CbGpPWpGaD
Octreotide—Hyperglycaemia—Doxorubicin—bone cancer	0.000249	0.00131	CcSEcCtD
Octreotide—Pneumonia—Doxorubicin—bone cancer	0.000248	0.00131	CcSEcCtD
Octreotide—Drowsiness—Doxorubicin—bone cancer	0.000247	0.0013	CcSEcCtD
Octreotide—Visual impairment—Methotrexate—bone cancer	0.000246	0.0013	CcSEcCtD
Octreotide—Hypersensitivity—Cisplatin—bone cancer	0.000244	0.00128	CcSEcCtD
Octreotide—Bradycardia—Epirubicin—bone cancer	0.000243	0.00128	CcSEcCtD
Octreotide—Neuropathy peripheral—Doxorubicin—bone cancer	0.000242	0.00127	CcSEcCtD
Octreotide—Jaundice—Doxorubicin—bone cancer	0.00024	0.00127	CcSEcCtD
Octreotide—Rhinitis—Epirubicin—bone cancer	0.00024	0.00126	CcSEcCtD
Octreotide—Urinary tract infection—Doxorubicin—bone cancer	0.00024	0.00126	CcSEcCtD
Octreotide—Conjunctivitis—Doxorubicin—bone cancer	0.00024	0.00126	CcSEcCtD
Octreotide—Hepatitis—Epirubicin—bone cancer	0.000239	0.00126	CcSEcCtD
Octreotide—Tinnitus—Methotrexate—bone cancer	0.000238	0.00126	CcSEcCtD
Octreotide—Hypoaesthesia—Epirubicin—bone cancer	0.000238	0.00125	CcSEcCtD
Octreotide—Asthenia—Cisplatin—bone cancer	0.000237	0.00125	CcSEcCtD
Octreotide—Pharyngitis—Epirubicin—bone cancer	0.000237	0.00125	CcSEcCtD
Octreotide—Cardiac disorder—Methotrexate—bone cancer	0.000237	0.00125	CcSEcCtD
Octreotide—Oedema peripheral—Epirubicin—bone cancer	0.000236	0.00124	CcSEcCtD
Octreotide—Haematuria—Doxorubicin—bone cancer	0.000235	0.00124	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—ATF1—bone cancer	0.000234	0.00242	CbGpPWpGaD
Octreotide—Hepatobiliary disease—Doxorubicin—bone cancer	0.000233	0.00123	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—GRM1—bone cancer	0.000233	0.0024	CbGpPWpGaD
Octreotide—Epistaxis—Doxorubicin—bone cancer	0.000233	0.00122	CcSEcCtD
Octreotide—Sinusitis—Doxorubicin—bone cancer	0.000231	0.00122	CcSEcCtD
Octreotide—Immune system disorder—Methotrexate—bone cancer	0.000231	0.00122	CcSEcCtD
Octreotide—Visual impairment—Epirubicin—bone cancer	0.00023	0.00121	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—IL3—bone cancer	0.00023	0.00238	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—IL3—bone cancer	0.000229	0.00236	CbGpPWpGaD
Octreotide—Diarrhoea—Cisplatin—bone cancer	0.000226	0.00119	CcSEcCtD
Octreotide—Alopecia—Methotrexate—bone cancer	0.000226	0.00119	CcSEcCtD
Octreotide—Bradycardia—Doxorubicin—bone cancer	0.000225	0.00119	CcSEcCtD
Octreotide—Mental disorder—Methotrexate—bone cancer	0.000224	0.00118	CcSEcCtD
Octreotide—Tinnitus—Epirubicin—bone cancer	0.000223	0.00117	CcSEcCtD
Octreotide—Erythema—Methotrexate—bone cancer	0.000222	0.00117	CcSEcCtD
Octreotide—Malnutrition—Methotrexate—bone cancer	0.000222	0.00117	CcSEcCtD
Octreotide—Cardiac disorder—Epirubicin—bone cancer	0.000222	0.00117	CcSEcCtD
Octreotide—Flushing—Epirubicin—bone cancer	0.000222	0.00117	CcSEcCtD
Octreotide—Rhinitis—Doxorubicin—bone cancer	0.000222	0.00117	CcSEcCtD
Octreotide—Hepatitis—Doxorubicin—bone cancer	0.000221	0.00117	CcSEcCtD
Octreotide—Hypoaesthesia—Doxorubicin—bone cancer	0.00022	0.00116	CcSEcCtD
Octreotide—Pharyngitis—Doxorubicin—bone cancer	0.00022	0.00116	CcSEcCtD
Octreotide—Oedema peripheral—Doxorubicin—bone cancer	0.000218	0.00115	CcSEcCtD
Octreotide—Immune system disorder—Epirubicin—bone cancer	0.000216	0.00114	CcSEcCtD
Octreotide—Back pain—Methotrexate—bone cancer	0.000215	0.00113	CcSEcCtD
Octreotide—Arrhythmia—Epirubicin—bone cancer	0.000214	0.00113	CcSEcCtD
Octreotide—Visual impairment—Doxorubicin—bone cancer	0.000213	0.00112	CcSEcCtD
Octreotide—Alopecia—Epirubicin—bone cancer	0.000211	0.00111	CcSEcCtD
Octreotide—Vomiting—Cisplatin—bone cancer	0.00021	0.00111	CcSEcCtD
Octreotide—Vision blurred—Methotrexate—bone cancer	0.00021	0.0011	CcSEcCtD
Octreotide—Mental disorder—Epirubicin—bone cancer	0.00021	0.0011	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—SMO—bone cancer	0.000209	0.00216	CbGpPWpGaD
Octreotide—Rash—Cisplatin—bone cancer	0.000209	0.0011	CcSEcCtD
Octreotide—Dermatitis—Cisplatin—bone cancer	0.000208	0.0011	CcSEcCtD
Octreotide—Malnutrition—Epirubicin—bone cancer	0.000208	0.0011	CcSEcCtD
Octreotide—Erythema—Epirubicin—bone cancer	0.000208	0.0011	CcSEcCtD
Octreotide—Ill-defined disorder—Methotrexate—bone cancer	0.000206	0.00109	CcSEcCtD
Octreotide—Tinnitus—Doxorubicin—bone cancer	0.000206	0.00109	CcSEcCtD
Octreotide—Anaemia—Methotrexate—bone cancer	0.000206	0.00108	CcSEcCtD
Octreotide—Flushing—Doxorubicin—bone cancer	0.000205	0.00108	CcSEcCtD
Octreotide—Cardiac disorder—Doxorubicin—bone cancer	0.000205	0.00108	CcSEcCtD
Octreotide—Flatulence—Epirubicin—bone cancer	0.000205	0.00108	CcSEcCtD
Octreotide—Tension—Epirubicin—bone cancer	0.000204	0.00108	CcSEcCtD
Octreotide—Nervousness—Epirubicin—bone cancer	0.000202	0.00107	CcSEcCtD
Octreotide—Back pain—Epirubicin—bone cancer	0.000201	0.00106	CcSEcCtD
Octreotide—Malaise—Methotrexate—bone cancer	0.000201	0.00106	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—SMO—bone cancer	0.0002	0.00207	CbGpPWpGaD
Octreotide—Muscle spasms—Epirubicin—bone cancer	0.0002	0.00105	CcSEcCtD
Octreotide—Immune system disorder—Doxorubicin—bone cancer	0.0002	0.00105	CcSEcCtD
Octreotide—Vertigo—Methotrexate—bone cancer	0.0002	0.00105	CcSEcCtD
Octreotide—Arrhythmia—Doxorubicin—bone cancer	0.000198	0.00104	CcSEcCtD
Octreotide—Nausea—Cisplatin—bone cancer	0.000197	0.00104	CcSEcCtD
Octreotide—Vision blurred—Epirubicin—bone cancer	0.000196	0.00103	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—TGFBR2—bone cancer	0.000196	0.00202	CbGpPWpGaD
Octreotide—Alopecia—Doxorubicin—bone cancer	0.000196	0.00103	CcSEcCtD
Octreotide—Cough—Methotrexate—bone cancer	0.000194	0.00102	CcSEcCtD
Octreotide—Mental disorder—Doxorubicin—bone cancer	0.000194	0.00102	CcSEcCtD
Octreotide—Ill-defined disorder—Epirubicin—bone cancer	0.000193	0.00102	CcSEcCtD
Octreotide—Convulsion—Methotrexate—bone cancer	0.000193	0.00102	CcSEcCtD
Octreotide—Erythema—Doxorubicin—bone cancer	0.000193	0.00101	CcSEcCtD
Octreotide—Malnutrition—Doxorubicin—bone cancer	0.000193	0.00101	CcSEcCtD
Octreotide—Anaemia—Epirubicin—bone cancer	0.000192	0.00101	CcSEcCtD
Octreotide—Agitation—Epirubicin—bone cancer	0.000191	0.00101	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—GNA11—bone cancer	0.000191	0.00197	CbGpPWpGaD
Octreotide—Flatulence—Doxorubicin—bone cancer	0.00019	0.001	CcSEcCtD
Octreotide—Chest pain—Methotrexate—bone cancer	0.000189	0.000998	CcSEcCtD
Octreotide—Myalgia—Methotrexate—bone cancer	0.000189	0.000998	CcSEcCtD
Octreotide—Arthralgia—Methotrexate—bone cancer	0.000189	0.000998	CcSEcCtD
Octreotide—Tension—Doxorubicin—bone cancer	0.000189	0.000996	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000188	0.000991	CcSEcCtD
Octreotide—Malaise—Epirubicin—bone cancer	0.000188	0.000989	CcSEcCtD
Octreotide—Discomfort—Methotrexate—bone cancer	0.000187	0.000986	CcSEcCtD
Octreotide—Nervousness—Doxorubicin—bone cancer	0.000187	0.000985	CcSEcCtD
Octreotide—Vertigo—Epirubicin—bone cancer	0.000187	0.000985	CcSEcCtD
Octreotide—Syncope—Epirubicin—bone cancer	0.000187	0.000983	CcSEcCtD
Octreotide—Back pain—Doxorubicin—bone cancer	0.000186	0.000981	CcSEcCtD
Octreotide—Muscle spasms—Doxorubicin—bone cancer	0.000185	0.000975	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—IGF1R—bone cancer	0.000184	0.0019	CbGpPWpGaD
Octreotide—Palpitations—Epirubicin—bone cancer	0.000184	0.000969	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—GNA11—bone cancer	0.000183	0.00189	CbGpPWpGaD
Octreotide—Loss of consciousness—Epirubicin—bone cancer	0.000183	0.000964	CcSEcCtD
Octreotide—Cough—Epirubicin—bone cancer	0.000182	0.000957	CcSEcCtD
Octreotide—Anaphylactic shock—Methotrexate—bone cancer	0.000182	0.000956	CcSEcCtD
Octreotide—Vision blurred—Doxorubicin—bone cancer	0.000182	0.000956	CcSEcCtD
Octreotide—Convulsion—Epirubicin—bone cancer	0.00018	0.00095	CcSEcCtD
Octreotide—Infection—Methotrexate—bone cancer	0.00018	0.00095	CcSEcCtD
Octreotide—Hypertension—Epirubicin—bone cancer	0.00018	0.000947	CcSEcCtD
Octreotide—Ill-defined disorder—Doxorubicin—bone cancer	0.000179	0.000941	CcSEcCtD
Octreotide—Nervous system disorder—Methotrexate—bone cancer	0.000178	0.000938	CcSEcCtD
Octreotide—Anaemia—Doxorubicin—bone cancer	0.000178	0.000938	CcSEcCtD
Octreotide—Thrombocytopenia—Methotrexate—bone cancer	0.000178	0.000936	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—SMO—bone cancer	0.000178	0.00184	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ATF1—bone cancer	0.000178	0.00184	CbGpPWpGaD
Octreotide—Chest pain—Epirubicin—bone cancer	0.000177	0.000934	CcSEcCtD
Octreotide—Myalgia—Epirubicin—bone cancer	0.000177	0.000934	CcSEcCtD
Octreotide—Arthralgia—Epirubicin—bone cancer	0.000177	0.000934	CcSEcCtD
Octreotide—Agitation—Doxorubicin—bone cancer	0.000177	0.000932	CcSEcCtD
Octreotide—Anxiety—Epirubicin—bone cancer	0.000177	0.00093	CcSEcCtD
Octreotide—Skin disorder—Methotrexate—bone cancer	0.000176	0.000929	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000176	0.000927	CcSEcCtD
Octreotide—Hyperhidrosis—Methotrexate—bone cancer	0.000176	0.000925	CcSEcCtD
Octreotide—Discomfort—Epirubicin—bone cancer	0.000175	0.000922	CcSEcCtD
Octreotide—Malaise—Doxorubicin—bone cancer	0.000174	0.000915	CcSEcCtD
Octreotide—Dry mouth—Epirubicin—bone cancer	0.000173	0.000913	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—IL3—bone cancer	0.000173	0.00179	CbGpPWpGaD
Octreotide—Vertigo—Doxorubicin—bone cancer	0.000173	0.000912	CcSEcCtD
Octreotide—Anorexia—Methotrexate—bone cancer	0.000173	0.000912	CcSEcCtD
Octreotide—Syncope—Doxorubicin—bone cancer	0.000173	0.00091	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—ATF1—bone cancer	0.00017	0.00176	CbGpPWpGaD
Octreotide—Palpitations—Doxorubicin—bone cancer	0.00017	0.000897	CcSEcCtD
Octreotide—Oedema—Epirubicin—bone cancer	0.00017	0.000895	CcSEcCtD
Octreotide—Anaphylactic shock—Epirubicin—bone cancer	0.00017	0.000895	CcSEcCtD
Octreotide—Loss of consciousness—Doxorubicin—bone cancer	0.000169	0.000892	CcSEcCtD
Octreotide—Infection—Epirubicin—bone cancer	0.000169	0.000889	CcSEcCtD
Octreotide—Cough—Doxorubicin—bone cancer	0.000168	0.000885	CcSEcCtD
Octreotide—Shock—Epirubicin—bone cancer	0.000167	0.00088	CcSEcCtD
Octreotide—Convulsion—Doxorubicin—bone cancer	0.000167	0.000879	CcSEcCtD
Octreotide—Nervous system disorder—Epirubicin—bone cancer	0.000167	0.000878	CcSEcCtD
Octreotide—Thrombocytopenia—Epirubicin—bone cancer	0.000166	0.000876	CcSEcCtD
Octreotide—Hypertension—Doxorubicin—bone cancer	0.000166	0.000876	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—IL3—bone cancer	0.000166	0.00172	CbGpPWpGaD
Octreotide—Tachycardia—Epirubicin—bone cancer	0.000166	0.000873	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000165	0.000871	CcSEcCtD
Octreotide—Skin disorder—Epirubicin—bone cancer	0.000165	0.000869	CcSEcCtD
Octreotide—Hyperhidrosis—Epirubicin—bone cancer	0.000164	0.000865	CcSEcCtD
Octreotide—Insomnia—Methotrexate—bone cancer	0.000164	0.000865	CcSEcCtD
Octreotide—Chest pain—Doxorubicin—bone cancer	0.000164	0.000864	CcSEcCtD
Octreotide—Arthralgia—Doxorubicin—bone cancer	0.000164	0.000864	CcSEcCtD
Octreotide—Myalgia—Doxorubicin—bone cancer	0.000164	0.000864	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—SMO—bone cancer	0.000164	0.00169	CbGpPWpGaD
Octreotide—Anxiety—Doxorubicin—bone cancer	0.000163	0.000861	CcSEcCtD
Octreotide—Paraesthesia—Methotrexate—bone cancer	0.000163	0.000859	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000163	0.000858	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—GNA11—bone cancer	0.000163	0.00168	CbGpPWpGaD
Octreotide—Discomfort—Doxorubicin—bone cancer	0.000162	0.000853	CcSEcCtD
Octreotide—Anorexia—Epirubicin—bone cancer	0.000162	0.000853	CcSEcCtD
Octreotide—Dyspnoea—Methotrexate—bone cancer	0.000162	0.000853	CcSEcCtD
Octreotide—Somnolence—Methotrexate—bone cancer	0.000161	0.00085	CcSEcCtD
Octreotide—Dry mouth—Doxorubicin—bone cancer	0.00016	0.000845	CcSEcCtD
Octreotide—Dyspepsia—Methotrexate—bone cancer	0.00016	0.000842	CcSEcCtD
Octreotide—Decreased appetite—Methotrexate—bone cancer	0.000158	0.000831	CcSEcCtD
Octreotide—Anaphylactic shock—Doxorubicin—bone cancer	0.000157	0.000828	CcSEcCtD
Octreotide—Oedema—Doxorubicin—bone cancer	0.000157	0.000828	CcSEcCtD
Octreotide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000157	0.000826	CcSEcCtD
Octreotide—Fatigue—Methotrexate—bone cancer	0.000157	0.000824	CcSEcCtD
Octreotide—Infection—Doxorubicin—bone cancer	0.000156	0.000823	CcSEcCtD
Octreotide—Pain—Methotrexate—bone cancer	0.000155	0.000818	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000155	0.000815	CcSEcCtD
Octreotide—Shock—Doxorubicin—bone cancer	0.000155	0.000815	CcSEcCtD
Octreotide—Nervous system disorder—Doxorubicin—bone cancer	0.000154	0.000812	CcSEcCtD
Octreotide—Thrombocytopenia—Doxorubicin—bone cancer	0.000154	0.000811	CcSEcCtD
Octreotide—Insomnia—Epirubicin—bone cancer	0.000154	0.000809	CcSEcCtD
Octreotide—Tachycardia—Doxorubicin—bone cancer	0.000153	0.000808	CcSEcCtD
Octreotide—Skin disorder—Doxorubicin—bone cancer	0.000153	0.000804	CcSEcCtD
Octreotide—Paraesthesia—Epirubicin—bone cancer	0.000153	0.000804	CcSEcCtD
Octreotide—Hyperhidrosis—Doxorubicin—bone cancer	0.000152	0.000801	CcSEcCtD
Octreotide—Dyspnoea—Epirubicin—bone cancer	0.000151	0.000798	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—ATF1—bone cancer	0.000151	0.00156	CbGpPWpGaD
Octreotide—Somnolence—Epirubicin—bone cancer	0.000151	0.000796	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—GNA11—bone cancer	0.00015	0.00155	CbGpPWpGaD
Octreotide—Anorexia—Doxorubicin—bone cancer	0.00015	0.000789	CcSEcCtD
Octreotide—Feeling abnormal—Methotrexate—bone cancer	0.00015	0.000788	CcSEcCtD
Octreotide—Dyspepsia—Epirubicin—bone cancer	0.00015	0.000788	CcSEcCtD
Octreotide—Gastrointestinal pain—Methotrexate—bone cancer	0.000148	0.000782	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—TGFBR2—bone cancer	0.000148	0.00153	CbGpPWpGaD
Octreotide—Decreased appetite—Epirubicin—bone cancer	0.000148	0.000778	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—IL3—bone cancer	0.000147	0.00152	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000147	0.000773	CcSEcCtD
Octreotide—Fatigue—Epirubicin—bone cancer	0.000146	0.000772	CcSEcCtD
Octreotide—Pain—Epirubicin—bone cancer	0.000145	0.000765	CcSEcCtD
Octreotide—Constipation—Epirubicin—bone cancer	0.000145	0.000765	CcSEcCtD
Octreotide—Urticaria—Methotrexate—bone cancer	0.000144	0.00076	CcSEcCtD
Octreotide—Abdominal pain—Methotrexate—bone cancer	0.000144	0.000756	CcSEcCtD
Octreotide—Body temperature increased—Methotrexate—bone cancer	0.000144	0.000756	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000143	0.000754	CcSEcCtD
Octreotide—Insomnia—Doxorubicin—bone cancer	0.000142	0.000749	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—TGFBR2—bone cancer	0.000142	0.00147	CbGpPWpGaD
Octreotide—Paraesthesia—Doxorubicin—bone cancer	0.000141	0.000744	CcSEcCtD
Octreotide—Dyspnoea—Doxorubicin—bone cancer	0.00014	0.000738	CcSEcCtD
Octreotide—Feeling abnormal—Epirubicin—bone cancer	0.00014	0.000737	CcSEcCtD
Octreotide—Somnolence—Doxorubicin—bone cancer	0.00014	0.000736	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—ATF1—bone cancer	0.000139	0.00144	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IGF1R—bone cancer	0.000139	0.00144	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Epirubicin—bone cancer	0.000139	0.000732	CcSEcCtD
Octreotide—Dyspepsia—Doxorubicin—bone cancer	0.000138	0.000729	CcSEcCtD
Octreotide—Decreased appetite—Doxorubicin—bone cancer	0.000137	0.00072	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—IL3—bone cancer	0.000136	0.0014	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000136	0.000715	CcSEcCtD
Octreotide—Fatigue—Doxorubicin—bone cancer	0.000136	0.000714	CcSEcCtD
Octreotide—Urticaria—Epirubicin—bone cancer	0.000135	0.000711	CcSEcCtD
Octreotide—Pain—Doxorubicin—bone cancer	0.000134	0.000708	CcSEcCtD
Octreotide—Constipation—Doxorubicin—bone cancer	0.000134	0.000708	CcSEcCtD
Octreotide—Abdominal pain—Epirubicin—bone cancer	0.000134	0.000707	CcSEcCtD
Octreotide—Body temperature increased—Epirubicin—bone cancer	0.000134	0.000707	CcSEcCtD
Octreotide—Hypersensitivity—Methotrexate—bone cancer	0.000134	0.000705	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—IGF1R—bone cancer	0.000134	0.00138	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—KIT—bone cancer	0.000133	0.00138	CbGpPWpGaD
Octreotide—Asthenia—Methotrexate—bone cancer	0.00013	0.000686	CcSEcCtD
Octreotide—Feeling abnormal—Doxorubicin—bone cancer	0.00013	0.000682	CcSEcCtD
Octreotide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000129	0.000677	CcSEcCtD
Octreotide—Pruritus—Methotrexate—bone cancer	0.000128	0.000677	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—TGFBR2—bone cancer	0.000126	0.0013	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—BRAF—bone cancer	0.000125	0.0013	CbGpPWpGaD
Octreotide—Hypersensitivity—Epirubicin—bone cancer	0.000125	0.000659	CcSEcCtD
Octreotide—Urticaria—Doxorubicin—bone cancer	0.000125	0.000658	CcSEcCtD
Octreotide—Body temperature increased—Doxorubicin—bone cancer	0.000124	0.000655	CcSEcCtD
Octreotide—Abdominal pain—Doxorubicin—bone cancer	0.000124	0.000655	CcSEcCtD
Octreotide—Diarrhoea—Methotrexate—bone cancer	0.000124	0.000654	CcSEcCtD
Octreotide—Asthenia—Epirubicin—bone cancer	0.000122	0.000642	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—EGFR—bone cancer	0.000122	0.00126	CbGpPWpGaD
Octreotide—Pruritus—Epirubicin—bone cancer	0.00012	0.000633	CcSEcCtD
Octreotide—Dizziness—Methotrexate—bone cancer	0.00012	0.000632	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—IGF1R—bone cancer	0.000119	0.00123	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TGFBR2—bone cancer	0.000116	0.0012	CbGpPWpGaD
Octreotide—Diarrhoea—Epirubicin—bone cancer	0.000116	0.000612	CcSEcCtD
Octreotide—Hypersensitivity—Doxorubicin—bone cancer	0.000116	0.00061	CcSEcCtD
Octreotide—Vomiting—Methotrexate—bone cancer	0.000115	0.000608	CcSEcCtD
Octreotide—Rash—Methotrexate—bone cancer	0.000114	0.000603	CcSEcCtD
Octreotide—Dermatitis—Methotrexate—bone cancer	0.000114	0.000602	CcSEcCtD
Octreotide—Headache—Methotrexate—bone cancer	0.000114	0.000599	CcSEcCtD
Octreotide—Asthenia—Doxorubicin—bone cancer	0.000113	0.000594	CcSEcCtD
Octreotide—Dizziness—Epirubicin—bone cancer	0.000112	0.000592	CcSEcCtD
Octreotide—Pruritus—Doxorubicin—bone cancer	0.000111	0.000586	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—IGF1R—bone cancer	0.000109	0.00113	CbGpPWpGaD
Octreotide—Vomiting—Epirubicin—bone cancer	0.000108	0.000569	CcSEcCtD
Octreotide—Nausea—Methotrexate—bone cancer	0.000108	0.000568	CcSEcCtD
Octreotide—Diarrhoea—Doxorubicin—bone cancer	0.000108	0.000567	CcSEcCtD
Octreotide—Rash—Epirubicin—bone cancer	0.000107	0.000564	CcSEcCtD
Octreotide—Dermatitis—Epirubicin—bone cancer	0.000107	0.000564	CcSEcCtD
Octreotide—Headache—Epirubicin—bone cancer	0.000106	0.000561	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—MDM2—bone cancer	0.000105	0.00109	CbGpPWpGaD
Octreotide—Dizziness—Doxorubicin—bone cancer	0.000104	0.000548	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—KIT—bone cancer	0.000101	0.00104	CbGpPWpGaD
Octreotide—Nausea—Epirubicin—bone cancer	0.000101	0.000532	CcSEcCtD
Octreotide—Vomiting—Doxorubicin—bone cancer	0.0001	0.000527	CcSEcCtD
Octreotide—Rash—Doxorubicin—bone cancer	9.91e-05	0.000522	CcSEcCtD
Octreotide—Dermatitis—Doxorubicin—bone cancer	9.9e-05	0.000522	CcSEcCtD
Octreotide—Headache—Doxorubicin—bone cancer	9.85e-05	0.000519	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—KIT—bone cancer	9.7e-05	0.001	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—BRAF—bone cancer	9.51e-05	0.000982	CbGpPWpGaD
Octreotide—Nausea—Doxorubicin—bone cancer	9.34e-05	0.000492	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—EGFR—bone cancer	9.21e-05	0.000952	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—JUN—bone cancer	9.14e-05	0.000944	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—BRAF—bone cancer	9.11e-05	0.000942	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MMP9—bone cancer	8.89e-05	0.000918	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—EGFR—bone cancer	8.83e-05	0.000913	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KIT—bone cancer	8.6e-05	0.000888	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—BRAF—bone cancer	8.08e-05	0.000835	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MDM2—bone cancer	7.97e-05	0.000823	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KIT—bone cancer	7.94e-05	0.00082	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—EGFR—bone cancer	7.83e-05	0.000809	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MDM2—bone cancer	7.64e-05	0.000789	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—BRAF—bone cancer	7.46e-05	0.000771	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—EGFR—bone cancer	7.23e-05	0.000747	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EGFR—bone cancer	7.18e-05	0.000742	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—JUN—bone cancer	6.92e-05	0.000715	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MDM2—bone cancer	6.77e-05	0.0007	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MMP9—bone cancer	6.74e-05	0.000696	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—JUN—bone cancer	6.64e-05	0.000686	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MMP9—bone cancer	6.46e-05	0.000667	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MDM2—bone cancer	6.25e-05	0.000646	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TP53—bone cancer	6.03e-05	0.000623	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—JUN—bone cancer	5.89e-05	0.000608	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MMP9—bone cancer	5.73e-05	0.000592	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EGFR—bone cancer	5.44e-05	0.000562	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—JUN—bone cancer	5.43e-05	0.000561	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MMP9—bone cancer	5.29e-05	0.000546	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EGFR—bone cancer	5.22e-05	0.000539	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EGFR—bone cancer	4.63e-05	0.000478	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TP53—bone cancer	4.57e-05	0.000472	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TP53—bone cancer	4.38e-05	0.000453	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EGFR—bone cancer	4.27e-05	0.000441	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TP53—bone cancer	3.89e-05	0.000401	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TP53—bone cancer	3.59e-05	0.000371	CbGpPWpGaD
